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Exogenous angiotensin II does not reduce plasma renin activity in
pregnancy-induced hypertension. B. Miranda, L. Ruilope, C. Paya, R.
Garcia Robles, J. M Alcazar, V. G. Millet, J. Sancho, and J. L.
Rodicio. J9 de Octubre and Ramón y Cajal Hospitals, Madrid, Spain.
Pregnancy is usually associated with a decreased pressor response to
angiotensin II (All) which is lost when hypertension appears. No
information is available on the manner in which angiotensin II influ-
ences the levels of plasma renin activity (PRA). To define this point,
progressive doses of All were infused for segmental 15 mm periods
until diastolic pressure (DP) increased by 20 mm Hg in five pregnant
women in which early detection of hypertension occurred at 21 to 23
weeks of gestation (Hyp Pr). Six normotensive pregnants (Norm Pr)
five non-pregnant female (F) and five males (M) were used as a control.
Basal and every 15 mm measurement of BP, PRA, and plasma aldos-
terone (PA) were performed. Results are depicted below (X SEM).
Control 4 to 8 ng/kg/min
Norm Pr PrNorm Pr Hyp Pr Hyp
PRA
PA
(DP)
5.5 0.8
6.0 0.3
0.0 0.9
18.1 2.4
14.7 4.8
0.0 0.0
1.7 0.6*
18.2 2.1
20.0 09*
16.1
41.8
20.0
2.8
11.0*
0.7*
* P < 0.01 vs. control.
F and M exhibited a pattern of responses similar to Norm Pr. We
conclude that a.) early hypertension in pregnancy is associated with
high values of PRA and PA, and b.) failure of circulating All to reduce
PRA may be a major alteration underlying the pathogenesis of Hyp Pr.
Left ventricular enlargement is abolished after long-term treatment of
essential hypertension. F. Arribas, B. Miranda, L. Ruilope, J. M.
Alcazar, J. Nieto, and J. L. Rodicio. P de Octubre Hospital, Madrid,
Spain. Left ventricular enlargement (LVE) on EKG is considered a bad
prognostic sign and constitutes a frequent finding among the hyperten-
sive population. Actual regression of LVE has been shown with some
types of antihypertensive therapy. We report the evolution of a group of
125 patients with EH followed for a 5-yr period, during which and in
order to maintain their blood pressure (BP) below 150/95, they received
l(hydrochlorothiazide + amiloride), 2 (1 + propranolol), or 3 (2 +
hydrallazine) drugs. The presence of LVE on EKG was assessed by
voltage and repolarization criteria. The EKG abnormalities were graded
as normal (N), left axis deviation or minimal voltage or repolarization
criteria (A), some voltage criteria plus repolarization alterations (B),
and as important LVE (C). During the follow-up period there was an
EKG improvement in 80.2% of cases with normalization in 50% (See
Table).
Initial
N
39.2%
A
22.4%
B
17.6%
-
C
20.8%
5 Yr 71.2% 24.0% 2.4% 2.4%
P 0.005 NS 0.005 0.005
The findings were independent of the number and type of
antihypertensive drugs administered. We conclude: 1) Improvement of
LVE pattern on EKG can reach normalization with long-term control of
BP in EH, 2) this appears to be independent of the therapeutic
requirements.
Usefulness of (1131) iodo benzylguanidine scintigraphy of the localization
of pheochromocytoma. J. M. Morales, C. Varela, R. Ramos, J. M.
Alcazar, L. M. Ruilope, M. Praga, V. G. Millet, and J. L. Rodicio. P
de Octubre Hospital, Madrid, Spain. The use of an iodinated guanidine
analogue (meta P3' iodobenzylguanidine) has been suggested as a new
aid to scanning for pheochromacytoma. We have studied its usefulness
in a series of six patients (three male, three female, aged 12 to 44 yr)
diagnosed as having pheochromocytoma by clinical and biochemical
studies. All of them elevated urinary excretion of catecholamines with
a predominium of norepinephrine. The scintigraphy showed clear
images at 72 hr, already visible at 24 and 48 hr, demonstrating a tumor
in the right adrenal gland in five cases and in the left in one. The
localization was confirmed in every case by echography and scanner.
All the patients were operated upon and an scintigraphy performed I to
3 months after tumor removal showed no deposit of the isotope. We
conclude that i's' benzylguanidine is a useful tool in the diagnosis and
localization of pheochromocytoma.
Effects of captopril (C) on the excretion of saline load in normotensives
and patients with essential hypertension, L. F. de Villa, L. Ruilope, B.
Miranda, M. de Urioste, J. M. Alcazar, J. M. Morales, 1. Bello, J.
Nieto, and J. L. Rodicio. 1-" de Octubre Hospital, Madrid, Spain.
Essential hypertensive patients (AHP) excrete a saline load more
rapidly than normotensive volunteers (NV). We have tested the hypoth-
esis that 1) converting-enzyme inhibition (CEI) restores the excretion of
a saline load to normal in EHP; 2) CU increases the excretion of a
saline load in NV. Nine EHP with established disease and eight NV
have been studied while on a sodium intake of 150 mEq/day. They had
2 liters of isotonic saline at a rate of 500 mI/hr. Urine was collected
hourly (Nan, Ku), plasma samples were drawn every 2 hr (PRA and
aldosterone), blood pressure (BP) and heart rate were monitored every
15 mm (Dynamap). The procedure was repeated after the oral intake of
25 mg of captopril 1 hr before the start in EHP and NV: a further
repetition was made in EHP after 10 days of CE! when BP was below
150/90 mm Hg. Sodium excretion increased (P < 0.05) after acute CEI
in normals but did not change in EHP. When compared to basal values,
10 days of C treatment reduced (P < 0.05) the urinary excretion of Na
in EHP to values similar to those found initially in NV. The evolution
of PRA and aldosterone was similar in every group showing a significant
decrease (P < 0.05). BP did not change in NV with CEI, but decreased
significantly after 25 mg of captopril in EHP, although it remained
higher than in NV (P < 0.05). We conclude that acute CU increases the
excretion of a saline load in NV and does not change the excretion in
EHP probably because of the simultaneous decrease of BP. Further
diminutions of BP with CE! restore to normal the excretion of a saline
load in EHP.
Implications of the plasma levels of vitamin A on the calcium-phosphate
metabolism and on blood lipids in hemodialysis. M. Praga, J. M.
Morales, P. Diaz Rubio, J. M. Martinez, F. Canizares, L. M. Ruilope,
M. C. Muñoz, V. G. Millet, J. M. Alcazar, and J. L. Rodicio. P de
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Octubre Hospital. Madrid, Spain. The plasma levels of vitamin A (VA)
have been measured in a group of 71 hemodialysis patients receiving
vitamins orally as a part of their treatment and showed values ranging
from 69 to 450 gr/dl (224 82 Sn). A positive correlation was found
between the dose of vA and its plasma levels (r = 0.67, P < 0.0025).
When compared with those of 30 normal volunteers, in 21 (Group I), vA
levels were within normal limits and the remaining (Group H) showed
elevated levels. Group H exhibited higher levels of total serum calcium
(9.7 0.5 mg/dl vs. 9.4 0.8, P < 0.05) and lower levels of phosphate
(5.4 1.2 mg/dl Vs. 6.2 1.6, P < 0.025) and PTH (1322 566 vs.
1784 642, P < 0.005). Group II also had higher serum triglycerides
levels (219 102 mg/dl vs. 172 63; P < 0.05). No difference existed
between both groups of patients for age, length of dialysis treatment.
residual renal function, anemia, hepatic and bone disease, nor pruritus.
Four months after the withdrawal of vA intake, no significant variation
was detected in Group I, but Group II showed a significant decrease of
plasma vA levels from 262 72 zgr/dl to 200 40 (P < 0.001) and of
total serum calcium (P < 0.05) that was accompanied by an opposite
effect on serum phosphate (P < 0.05). No significant change was
observed in serum triglycerides. We conclude that the finding of
elevated plasma vA levels is related to its intake and modulate the
calcium-phosphate metabolism within influencing blood lipids.
In vitro granulocyte adherence: A new parameter of biocompatibility.
J. Garin, A. Martin-Malo, R. Perez, L. G. Burdiel, D. Castillo, E.
Andres, J. Gomez, E. Moreno, A. Torres, and P. AIjama. Ciudad
Sanitaria Reina Sofia, Cordoba, Spain. Hemodialysis (HD) with
cuprophan dialyzers (CU) is associated with a striking increase in
granulocyte adherence (GA), which is mediated by a plasma factor. We
have tested the hypothesis that the in vitro activity of this factor reflects
the biocompatibility of the dialyzer. GA was measured with a nylon
fiber column assay and the study was undertaken in nine patients
sequentially treated with CU, ethylenevinylalcohol (EVAL),
polyacrylonitrile (AN-69), and polysulphone (PSF) membrane dialyz-
ers. Pre-HD blood cells were resuspended in plasma drawn at IS mm of
HD, incubated, and tested for GA changes. The same experimental
set-up was repeated with blood cells from ABO-compatible donors. HD
plasma increased GA + 234% of pre-HD value with CU and + 120%
with EVAL (P < 0.001), whereas this increment was only + 6% with
AN-69, and PSF (NS). The degree of HD-induced neutropenia, as index
of biocompatibility, correlated with GA increase. The GA increasing
factor was not modified by heating the plasma to 56C for 30 mm before
incubation (CU, + 214%; EVAL, + 118%, and AN-69, + 2%). Similar
results were obtained when using granulocytes from ABO-compatible
non-uremic donors incubated with patients 15-mm HD plasma. The
ability of 15-mm HD plasma to increase GA depends on the type of
membrane and is an important determinant of its biocompatibility. In
vitro GA constitutes a reliable model test system for estimation of the
blood compatibility of dialyzer membranes.
Acetate in the dialysis fluid: Is it really harmful? A. MartIn-Malo, E.
Andrés, D. Castillo, L. G. Burdiel, R. Perez, J. Gomez, E. Moreno, and
P. Aljama, Ciudad Sanitaria Reina Sofia, Cordoba, Spain. The main
symptoms of hemodialysis intolerance are attributed to the acetate in
dialysate. Dialysis hypoxemia is a routine consequence of dialysate in
which the alkalinizing agent is acetate. To know whether the dialysis
symptomatology is related directly to acetate or to the observed
hypoxemia, a double blind study was undertaken. Ten regular dialysis
patients were studied in 2 consecutive sessions receiving either nasal
oxygen (0) or compressed air (A) at 3 liter/mm in identical conditions of
urea clearance and acetate mass transfer. Acetate plasma levels, Po2
and Pco2 were measured hourly and a symptom score was established
for presence and severity of nausea, vomiting, headache, cramps, and
chest pain. There were no significant differences between the two
groups with respect to the mean blood pressure drop (-' 15.3 and —
15.8% of the predialysis value). Acetate plasma level increased in a
similar profile with both procedures until the third hour of dialysis (3.82
mEq/liter with 0 and 3.83 with A, P < 0.001). However, hypoxemia
only occurred during A (from 95 mm Hg to 79, P < 0.005). There was
a significant correlation between blood pressure drop and acetate level
increased (r = 0.78, P < 0,020). Dialysis symptoms during 0 were 3.9 of
the score and 17 during A (P < 0.005). We conclude that although
dialysis symptomatology is multifactorial, the acetate in the dialysate is
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a determinant factor of arterial hypotension, whereas hypoxemia de-
termines the other symptoms of dialysis intolerance, which can be
minimized with the administration of supplemental oxygen.
Continuous arteriovenous hemofiltration: Preliminary experience with
high surface area hemofilters. D. Castillo, A. MartIn-Malo, L. G.
Burdiel, R. Perez, E. Andrés, J. Gomez, E. Moreno, and P. AIjama.
Ciudad Sanitaria Reina Sofia, Cordoba, Spain. Continuous arteriove-
nous hemofiltration (CAVH) has been introduced recently in the
management of acute renal failure patients with severe cardiovascular
instability. However, due to the relative small filtration rates when
compared with conventional hemofiltration, the control of uremia is
sometimes troublesome, particularly in hypercatabolic patients. We
have tried to solve this problem using 2 m2 hemofilters located between
femoral artery and vein cannulations without blood pump in five
patients. The length of sessions varied between 17 and 72 hr and the
filtration rate between 5.3 and 13.5 mI/mm. No patient demonstrated a
significant drop in arterial pressure and the heart rate remained stable.
There was a good correlation between filtration fraction and ultrafiltrate
volume (r = 0.85), but this parameter was independent of the blood flow
evaluated by the hematocrit differences. The uremic control was
satisfactory even in hypercatabolic patients. Despite monitored contin-
uous heparinization, clotting of the filter did occur and it was necessary
to use a fresh one every 36 to 48 hr. We conclude that CAVH can be
undertaken with high surface hemofilter. It is possible to control the
uremic status satisfactorily with no need of additional hemodialysis.
The only problem to bear in mind is the frequent clotting of the filter,
which suggests the use of a new one every 36 hr.
Eosinophilia (E D) plasma IgE levels and total lymphocytes population
(LP) in patients treated with hemodialysis with ethylenvinylalcohol
(EVAL) fiber. J. Aranzabal, P. Gómez-UIlate, M. Urra, A. Arri eta, M.
L. Velazquez, M. D. GarcIa-Masdevall, R. Saracho, J. Gainza, J.
Otxaran, 1. Lampreabe. Sección de lnmunologIa, Servicio de
NefrologIa, CS. de Ia S.S. Cruces, Baracaldo, Spain. We have studied
10 patients with ED during 1½ years, and we have found high levels of
plasma IgE (236,30 505,40 vs. 16,59 30; P0.0025) and increase in
ratio T Helper/T Supressor (H/S 2.07 1.14 vs. 1.53 0.5; P < 0,005)
lymphocytes, which is attributed to an increase of the helper lympho-
cytes (OKT4) (46.42 12.46 vs. 40.75 8.68; P 0.025) and fall of the
supressor lymphocytes (OKT8) (22.65 8.34 vs. 26.83 9.98; P 0,05).
We have not found significative changes in total LP (OKT3) (59.41
11.52 vs. 61.50 8.26). These patients have been treated in HD with
EVAL fiber during 3 months, and no changes have been found in total
eosinophils, (670.82 654.08 vs. 720.65 1014.52) either plasma IgE
levels (254.33 558.25 vs. 214.20 + 426.36) or total LP (H/S 2.08
1.46 vs. 2.36 1.4; OKT3 55.6 19.36 vs. 51.80 12.88; OKT4 42.90
15.44 vs. 38.60 14.8; OKT8 21.3 7.58 vs. 19.7 12.82). We
think the ED is a hypersensitivity-mediated event. Besides cuprophan
membrane, there are other elements in 1-ID which might be implicated
in ED.
Serum levels of 82 microglobuline (B2MG) and C reactive protein
(CRP) in the recent renal transplant and its value in acute rejection (AR).
P. Górnez-UIIa:e, J. Gainza, J. Otxaran, R. Saracho, J. Aranzabal, A.
Arrieta, M. L. Velazquez, M. D. GarcIa-Masdevall, I. Lampreabe.
Sección de InmunologIa y Servicio de NefrologIa, C.S. de Ia S.S.
Cruces-Bilbao, Spain. We have studied retrospectively 24 recipients of
transplants done from June, 1983 to April, 1984 (all cadaveric allografts)
and their relation with plasmatic levels of B2MG and CRP during the
first 14 post-transplant days in an attempt to find some value in early
diagnosis for AR. We have found a progressive diminution in the levels
of B2MG in all the recipients with functioning allografts, starting at
basal pre-transplant levels, which do not correspond to a normal
distribution. They have presented 12 episodes of AR (50%), all showing
early increases in the levels of B2MG by post-transplant day 5'08
2'62, evidencing a posteriori that the treatment of the crisis with
pulsotherapy was done on day + 8'66 3'92, with a significant
statistical difference. In five patients, increase of the levels of B2MG
without clinical data of AR was found (positive errors, 20.83%). The
levels of CRP are less specific than those of B2MG, evidencing an
increase for some in: a) 11 of the 12 AR episodes, b) in the first 4
post-transplant days, and c) increasing in only five of the patients who
586 Abstracts
had an B2MG increase without rejection. We conclude: 1) B2MG can
give an early prediction of AR crisis with 72 to 100% accuracy (P <
0.05), and 2) the parallel determination of levels of CRP and B2MG
increase accuracy, decreasing the occurrence of positive errors to
4.16%.
Infection with the human polyomavirus in renal transplant patients. J.
Otxaran, A. GarcIa-Riego, R. Mufliz, J. Cuiñas, J. M. Rivera, J,
Aranzabal, R. Saracho, J. Gainza, P. Gómez-Ullate, I. Lampreabe.
Servicio de Anatomia Patológica y Servicio de Nefrologla, Hospital de
Cruces, Bilbao, Spain. Infection with the human polyomavirus was
studied in 45 immunosuppressed renal transplant patients with a graft
functioning at least during 4 months and up to 4 yrs. Urine cytologic
studies and electron microscopy were used to assess viral activity.
Polyomavirus excretion in urine was detected in 10 of 45 patients (22%).
Polyomavirus excretion in urine was associated with urinary tract
infections (45%), sepsis (10%), patients with virus HB (20%), acute
respiratory infection (40%), obstructive uropathy with ureteral stricture
(20%), serologic titers of CMV  1/64(20%), and titers of herpes 1/64
(20%). There was no difference in the human polyomavirus infection
incidence with low or high doses of corticosteroids. We conclude that
the polyomavirus infection appears without clinic manifestations and
that it was not neoplasic. We studied its relationship to its activation
under conditions of inmunosuppressive therapy.
Acute renal failure (ARF) in children (C). M. Rengel, P. Caro, J.
Fdez-Llebrez, F. Vargas, F. Gómez, and L. Garcia. NefrologIa Pedi-
dtrica. Hospital Provincial, Madrid, Spain. Available information
about ARF in C is meager. We present our experience on 71 C with 73
episodes of ARF (44 males and 27 females) from 1975 to May 1984. The
C were aged 2 days to 14 years, with a major incidence in the first year
of life (44%). Diagnosis of ARF was established by the classical
parameters in blood and urine. ARF was divided in pre-renal 8.2%;
post-renal 13.7%; all were males with posterior urethral valves, and
renal 78.8%. In this group, hemolitic uremic syndrome (29.8%) reached
the major incidence, followed by hypernatremic dehydration (HD)
(21%), greater in males by inadequate diet, glomerulonephritis (10.5%),
hypertension (5.3%), nephrotoxicity (5.3%), tumors (5,3%),
hypercalcemia (3.5%), and acute interstitial nephritis (1.8%). Non-
oliguric ARF rate reached 39.7%. Precocious dialysis treatment was
started in 58.9%. The overall mortality was 19% during oligoanuric
period of HD and S. Total recovery was achieved in 60.3%, only two C
started chronic hemodialysis. In conclusion, ARF in C is more frequent
in the first and second year of life, with a major incidence in males,
many of whom underwent HD because of inadequate diet. The majority
of cases were oliguric ARF. Prognosis improved with the regular use of
dialysis and other techniques of treatment, so the overall mortality rate
is lower and the recovery higher.
Effect of a synthetic prostacydlin analogue (ZK 36374) on blood
pressure (BP) and renal handling of water and electrolytes in rats. V.
Lahera, V. Cachofeiro, F. J. del Cañizo, F. Durán, J. Parada, F. J.
Rodriguez, and J. A. F. Tresguerres. Cat. Endocr. Exptal., Dpto.
Fisiol., Fac. Med., Univ. Camp!., Madrid, Spain. ZK 36374 was
intrajugulary administered via an osmotic pump to rats submitted to
different experimental situations. Four weeks after the implantation of
a clip in the renal artery or sham operation to 34 male Wistar rats, half
of them were loaded with 5% NaCl in the diet: 4 weeks after ZK 36374
was infused during a week. BP diuresis, natriuresis, and kaliuresis was
measured before beginning, on days I and 7, and I week after the end
of the treatment. After 24 hr of administration, BP decreased in all
groups (P 0.001), except in control animals. The decrease was main-
tained until day 7, except for the two salt-loaded groups. One week after
the end of the infusion, every group returned to pre-treatment levels.
On the first day of treatment, diuresis significantly decreased in both
salt-loaded groups (P 0.01), and recovered previous values in day 7.
Natriuresis and kaliuresis decreased in all the groups in day I, recov-
ered levels at day 7, and increased again one week after the end of
treatment in both salt-loaded groups. The ZK 36374-induced hypoten-
sion is probably due to a direct vasodilator effect, without modifying
diuresis and urinary electrolyte excretion.
Hepatocyte handling of soluble IgA aggregates in experimental IgA
nephropathy. E. Gonzalez, J. Sancho, J. Gonzalez, R. Blasco, A.
Barat, R. Garcia Hoyo, L. Lozano, J. Egido, and L. Hernando.
Fundación Jiménez DIaz, Madrid, Spain. The purpose of this work was
to examine if a defect in the handling of IgA aggregates (A-IgA) by the
liver could be involved in the development of an experimental IgA
nephropathy. Radiolabelled soluble A-IgA were sequentially injected in
ICR-Swiss mice receiving 3 mg/week of Dextran-suiphate (Dx) i.p.
Although after I mg Dx injection, 50% of mice had IgA deposits in the
mesangium, this percentage diminished to control values from two
through 11 injections of Dx. At 24 injections, more than 85% of
immunized mice had IgA deposits and mesangial proliferation. Previous
to the increase in the IgA deposits, we had observed a delayed
clearance in Dx-mice (tl/2 3.3 + 0.2 mm) in relation to controls (0.8
+ 0.02, P0.001), due to decreased liver localization. The percentage of
isolated hepatocytes with IgA-FcR, determined by rosette formation
with IgA immunobeads (1-IgA), decreased in relation to controls (38 +
7 vs. 66 + 6 at injections). By contrast, I.IgA rosettes on Kupifer cells
increased (24.6 + 6 vs. 7.1 + I in controls) with a close correlation with
the frequency of IgA deposits. In summary, it is suggested that a
defective clearance of IgA immune complexes by hepatocytes might be
a prerequisite for the appearance of IgA nephropathy in mice.
Effect of virus B antigen in kidney transplant relationship between host
response to virus B infection and survival of the graft. J. J. Piaza Perez,
V. Alvarez Chiva, J. Egido de los Rios, V. Carreño, L. Hernando
Avendano. Transplant Unit, Fundacion Jimenez Diaz, Madrid, Spain.
Wecorrelated host response to virus B infection with the survival of the
graft, the titers of previous lymphocytotoxic antibodies, and the inci-
dence of biochemical chronic liver disease. For these purposes, we
divided 93 transplanted patients into three groups according the sero-
logical virus B studies performed during their previous hemodialysis
period: 1) HBs AG+, 2) Anti HBs+, and 3) HBs Ag(—), Anti liBs (—).
Chronic
HLA antibodies liver
disease,
%
Graft
survival,
yearsN <25% > 25%
HBs Ag(+) 20 1/20 (5) 1/20 (5) 9/20 (45) 78 78 63
Anti-HBs(+) 36 15/28 (53) 5/28 (17) 11/36 (30) 65 54 47
HBs Ag(—)
Anti HBs(—) 39 6/28 (25) 2/28 (7) 16/39 (41) 76 57 43
The groups were matched for source of kidneys, age, sex, number of
transfusions, and date of transplantation. These data indicate that 1)
chronic carriers of HBs Ag have better graft outcome than Anti HBs+
and HBsAg (—) anti HBs(—) patients (P <0.001),2) they have also less
anti HLA antibodies and to a lower titer than anti HBs(+), 3) this
probably reflects that HBs Ag+ are less immunoreactive (low respond-
ers), justifying the better results, and 4) chronic liver disease is not
correlated with antigenemia and occurs with almost equal frequency in
HBs Ag negative recipients.
Study of the mononuclear phagocytic system and hepatocytes function
on the rat. G. Herrero Beaumont, E. Gonzalez, J. Sancho, and J.
Egido. Servicio de Nefrologia, Fundacion Jimenez Diaz, Madrid,
Spain. Soluble immune complexes (IC) are predominantly taken up by
the liver. Recently, we have demonstrated that hepatocytes participate
actively in this process (Immunology, in press). Since an association
between glomerulonephritis and dysfunction of the mononuclear
phagocytic system has been suggested, we have used radiolabelled,
aggregated IgG (A-IgG) to detect altered hepatocyte or MPS activity in
a chronic serum sickness model induced in rats by daily i.p. injections
with high doses of ovoalbumin. Rats with nephritis had a delayed blood
clearance of A-IgG (tl/2 = 4.07 + 1.2 ml/min) in comparision with
control rats (tl/2 = 2.4 + 0.8 mm) (P0.05), and also an increased kidney
uptake (2.7 + 1.5 vs 1.2 + 0.8, P 0.05). The percentage of isolated
hepatocytes and Kupifer cells with IgG Fc receptor (R) was determined
by rosette formation with IgG immunobeads. In rats with nephritis, the
percentage of Kupifer cell and hepatocytes IgG FcR was increased
(about twofold) in relation with control rats. The A-IgG binding
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capacity of Kupifer cells was modulated by the injection of ovoalbumin.
These results show that a delayed clearance of IC exists in rats with
serum sickness and that the increase in the expression of IgG FcR by
the chronic IC stimulation does not improve the global function of MPS
and hepatocytes.
Renal handling of water and electrolytes in rats with chronic and
progressive portal hypertension. A. Blanchart, M. D. Fernández-Mu-
noz, C. Caramelo, L. Hernando, and J. M. López-Novoa, Fundación
Jiménez DIaz, Madrid, Spain. Changes in renal function induced by
saline infusion (3% body wt) were studied in rats with a chronic and
progressive model of portal hypertension (CPH) and in a control group.
CPH showed increased portal pressure (23.87 4.59 vs 8.05 1.12cm
H20, P < 0.01) and portal systemic shunting. Arterial pressure was
similar in both groups. In basal condition, CPH presented lower
glomerular filtration rate (GFR) (1.92 0.19 vs. 2.78 0.19 mI/mm, P
<0.01), renal plasmatic flow (RPF) (4.3 0.3 vs. 5.8 0.6 mI/mm, P
<0.01), and urinary volume (Uv) (6.5 0.7 vs. 8.8 2.6 mI/mm) than
control rats, but electrolyte excretion was not significantly different.
After saline infusion, Uv (11.35 1.59 (CPH) vs. 20.61 3.15
(controls) moles/min, P < 0.01), osmolar excretion (12.2 1.48 vs.
18.1 2,00, Osm/min, P < 0.01) and sodium excretion (1.52 0.31
vs. 3.31 0.65 smoles/min, P <0.01) in CPH had minor augmentation
compared to controls. Nevertheless, there were no statistically signif-
icant differences in GFR and RPF between both groups. These results
suggest that chronic portal hypertension results in impairment of GFR,
RPF, and Uv in basal condition. With expansion of the extracellular
volume, GFR and RPF reach normal values, but the diuresis and
natnuresis are less enhanced that in the control group.
Glomerular nephropathy in persons older than 50 years. J. Nunez
Nuñez, H. Calvete Garcia, H. Oliva Aldamiz, A. Barat, S. Casado
Perez, L. Hernando Avendaño. FundaciOn Ji,nénez DIaz, Madrid,
Spain. Renal biopsies have been obtained at our hospital from 590
patients aged between 1 to 80 years from 1972 until 1982. Among them,
we have chosen 74 patients with ages equal or superior to 50 years old
who presented glomerular pathology. Forty-two were men and 32 were
women. Their histologic diagnoses were: minimum changes, 2 (2.8%),
focal and segmentary hyalinosis, 6 (8%), membranous, 20 (27%),
membranoproliferative, 20 (27%), mesangial, 11 (14.8%), intra- and
extracapillary proliferative, 11(14.8%), and 4 (5.6%) corresponded to
less frequent diagnostics. Comparing the percentage of each glomerular
nephropathy with the 516 persons younger than 50 years, we found:
minimum change glomerulopathies in 50 (9.6%), focal and segmentary
hyalinosis, 73 (14%), membranous, 43 (9%), membranoproliferative,
147 (29%), mesangial, 158 (30%) and intra- and extracapillary prolifer-
ative, 26 (5%). These results show that, in ages greater than 50 years,
the most frequent diagnostics were mesangiocapillary glomerulonephri-
tis and membranous glomerulonephritis; meanwhile, the most frequent
ones of patients younger than 50 years were mesangiocapillary and
mesangial, the membranous diagnostic being less frequent. We com-
pare also the development of different nephropathies in relation with
age and possible therapeutic effects of immunodepressants and
corticosteroids.
Effect of PAF-acether on renal function in dogs. J. C. Santos, E. Sanz,
C. Caramelo, L. Hernando, and J. M. Lopez Novoa. Nephrology
Service, Fundacion Jitnenez Diaz, Madrid, Spain. The effect of PAF-
acether infusion in renal artery was studied in mongrel dogs. The
concentrations used were from 10-8 to lO M, during a 20-mm period
each. RBF (magnetic flowmeter) and arterial pressure (AP) were
continuously recorded and urinary volume, GFR, and fractional excre-
tion of Na, Cl, and K were measured separately from both kidneys.
Electrolytes, osmolality, and hematocrit in blood were measured also.
No differences were observed in Osm nor in plasma electrolytes.
10-8 10 10—6 l0
%PA
FSR
tO.09±l
0.35 3 t 2.11±28.61 5 1.03±328.4 9 6.7±386.4
Hto 1.1 4 11.2 6 f 16.4 9 54 7
Results of AP, RBF, and hematocrit are shown in the table. With
l08and iO i infusions, FENa and urinary volume decreased
significatively in the perfused kidney (2.26 0.35 vs. 3.06 0.67%and
1.29 0.23 vs. 1.92 0.35 ml/min, respectively). With higher
concentrations, both parameters and RBF fell drastically. In conclu-
sion, PAF-acether in concentrations between 10-8 and l0induces a
fall in FENa and urinary volume. At higher concentrations, it induces a
severe impairment of the renal function secondary to the abolishment of
RBF.
Presence of PAF-acether in blood during hemodialysis (HD) and its
relation with dialysis leukopenia. A. González-López, S. Fernandez-
Gallardo, C. Caramelo, P. Iflarrea, L. Hernando, and M. Sanchez
Crespo. Fundación Jimenez DIaz, Madrid, Spain. Platelet activating
factor (PAF-acether) is an inflammatory mediator whose ability to
induce neutrophil aggregation and degranulation is observed at concen-
trations lower than those required to activate platelets. Recently, a
direct procedure for PAF-acether measurement in blood has been
described in our laboratory (Biochem Biophys Res Comm, in press).
Five hemodialysis patients were studied with measures of PAF-acether
and leukocyte and platelet counts at different times of an HD session.
All HD were performed with Cuprophan capillary dialyzers of 1.1 and
1.3 m2, and the samples were obtained from the venous line of the
dialyzer at 0, 1, 2, 3, 4, 5, 15, 30, 120, and 240 mm. All the patients
showed a 78% decrease in the leukocyte count between 15 and 30 mm
with an almost complete recuperation at 120 mm. A reduction of about
20% was also observed in platelet count. In all patients a peak of
PAF-acether was detected between 5 and 30 mm. of HD. In three of
them, maximal PAF-acether concentration preceded the leukopenia
and in the other two the peak was present simultaneously or immedi-
ately after the leukopenia. These data suggest that PAF-acether could
be one of the polymorphonuclear stimulators involved in hemodialysis
leukopenia.
The Lewis system in renal transplantation. R. Marcén, C. Zamora, R.
Martin Hernández, J. L. Teruel, F. Liaño, C. Quereda, andf. Ortuño.
Servicio de Nefrologia, Centro Ra,nOn y Cajal, Madrid, Spain. The
goal of the present study was to examine the effect of the Lewis
antigens on cadaver kidney graft survival. We analyzed Ill recipients
and 47 donors. Two years acturial graft survival, according to Lewis
recipient phenotype, was as follows: Le (a—b+), 67%, Le (a+b—), 56%
and Le (a—b—), the graft survival was 67% vs. 45%, P < 0.05. These
differences could be explained by the distribution of the Lewis antigens
in the general population, Le (a—b+) recipients have higher possibility
to receive a compatible transplant than the other two groups, Le
(a+b—) and (a—b—). Furthermore, Lewis matched transplants had
better survival rates than Lewis mismatched (67% vs. 45%). There were
not signilicative differences between the groups in relation to DR
matching and transfusion. Our data seem to suggest that Lewis antigens
play an important role in transplant survival.
Comparative study of nephrotic syndrome (NS) with diffuse 1gM
deposits and focal glomerular sclerosis (FGS). A. Gonzalo, F. Mampaso,
T. Saguer, L. Orofino, C. Quereda, and J. Ortuño. Servicio de
NefrologIa, Ceniro RamOn y Cajal, Madrid, Spain. Thirty adult pa-
tients with primary nephrosis are studied. Clinical course of 15 ne-
phrotic patients with diffuse deposits of 1gM was compared with that of
15 patients with FGS on their first renal biopsy. Histological diagnosis
NS + 1gM FGS
Number of cases 15 15
Mean age, yr 23 29
Initial response
Spontaneous remission 1 1
Steroid responders 9 5
Mean follow-up, yr 3.8 3.6
Present status
Remission 13 9
Persistent NS 1 3
Chronic renal failure 1 3
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was performed by light, immunofluorescence, and electron microscopy.
All patients received the same therapy. Hypertension was present in
sixpatients with FGS (two at onset and four thereafter). Vascular
lesions were observed in seven cases with FGS (one hypertensive
patient and six normotensive at time of biopsy). All FGS without
hypertension nor vascular lesion were in remission. In summary, FGS
shows a short-term prognosis worse than NS with diffuse 1gM deposits.
In addition, patients with vascular lesions and hypertension in FGS
seem to have a more severe prognosis.
Monitoring of adherence to antihypertensive treatment. L. Orte, R.
Marcén, F. Garcia, J. L. Teruel, R. Matesanz, J. G. Revalderla, C.
Quereda, and J. Ortuño. Servicio de NefrologIa, Centro Ramón y
Cajal, Madrid, Spain. A major problem in antihypertensive treatment
control is the assessment of adherence to therapy. We studied 52
essential hypertensives, 32 male and 20 female, mean age 50.9 10.3
yr, on propranolol (PR) therapy and salt-free diet. Compliance was
assessed by measuring urine sodium excretion and PR blood levels by
spectrofluorometry. Eighteen patients (35%) had a urine sodium excre-
tion < 100 mEq/24 hr and 36 patients (69%) seemed to take the drug
correctly (basal blood level of PR  25% of the reached peak after
taking correspondent dose). There was a significant difference between
the percentage of patients who ate salt-free diets and those following
drug regime (P < 0.001). Blood pressure was under control (DBP < 95
mm Hg) in 32 patients (61.5%), 25 out of 36 in the group who take drug
therapy correctly, and seven out 16 patients of those who did not follow
the treatment well. The percentage of hypertensive patients appeared to
be taking their prescribed medicines was acceptable, but it could be
improved; however, the adherence to salt-free diet was poor. Blood
level monitoring of PR is a great help in management of antihyperten-
sive treatment.
Glomerulonephritis (GN) and hypertension (HT). L. Orofino, C.
Quereda, L. One, A. Gonzálo, A. Fernández, and J. Ortuño. Servicio
de Nefrologia, Centro Ramón y Cajal, Madrid, Spain. The study of the
relationship between ON and HT must take into account both preva-
lence of HT in normal population and renal function level, as well as
histological diagnosis. We analyze the presence of HT in 3.477 controls
and 303 patients with biopsied GN followed during a 6 years period: 54
Minimal Changes; 29 Membranous; 41 Focal Sclerosis; 42
Membranoproliferative; 83 Idiopathic IgA; 34 diffuse Mesangial 1gM; 15
Acute Endocapillar ON; and 5 Rapidly Progressive-.—GN (Crescents).
The incidence of HT was 23,4% in GN and 12,8% in normals (p <
0,001). However the 249 GN with normal GFR had an incidence of
13,2% (N.S.) which increased to 17.7% along the evolution (N.S.).
Incidence of HT was higher in Focal Sclerosis (27,6%) and Membra-
nous (26%) than in Membranoproliferative (11%), IgA (9%) and 1gM
(12%). After 6 years only the 23% of HT patients remains with normal
GFR, but the 86.7% of normotensive patients has normal GFR (p <
0,001). After 6 years, the 97,5% of the nephrotics normotensives
remains with normal GFR. CONCLUSIONS: 1.—Hypertension is
closely associated with GN. 2.—However, the incidence of HT in GN
with normal GFR is similar than in normals, except in Focal Sclerosis.
3.—The association of HT with GN is of bad prognosis.
Progression of vascular calcifications in hemodialysis patients. R.
Matcsanz, E. M. Escobar, L. Orofino, R. M. Hernández, A.
Fernández, and J. Ortuño. Servicio de NefrologIa, Centro Ramon y
Cajal, Madrid, Spain. The appearance or increase of calcifications of
great vessels (CGV) was evaluated in 342 follow-up yearly periods of
155 HD patients since the start of treatment (1 to 5 yr). CGV progres-
sion was found in 37 periods (18%), differentiated by an older age (49
7 vs. 37 + 13, P < 0.001), longer hypertension history (75 vs. 35 months
+13, P < 0.001), greater Ca levels (9.25 0.6 vs. 9.0 0.9, P <0.05),
with similar serum Cr, BUN, P and AP, CaCo3 and (OH)3 Al dosis and
Ca dialysate, while they received less vitamin D (16 vs. 43%), probably
because they were considered higher risk patients for CGV. There was
no correlation with subperiostal resorption, bone pain nor fractures, but
there was with pruritus (P < 0.05), vertebral osteopenia (P < 0.001),
and small vessels calcification. CGV did not correlate with hyperten-
sion control, cardiomeagly, nor EKG changes. Beta blocker prescrip-
tion was greater in the group without CGV progression (P < 0.01).
Previous vascular situation (age and hypertension) in the face of slightly
greater Ca levels and indirect signs of t PTH seem to facilitate CGV
progression. Beta blockers could prevent them perhaps through the
control of f PTH and/or hypertension.
Diabetic and non-diabetic nephropathy in patients with diabetes
mellitus. A. Gonzalo, F. Mampaso, C. Quereda, A. Giménez, L.
Orofino, N. Gallego, and J. Ortuno. Servicio de Nefrologia, Centro
Ramón y Cajal, Madrid, Spain. Kidney biopsy was performed in ten
patients with diabetes (two cases Type I and eight Type H) for renal
involvement inconsistent with natural history of diabetic nephropathy.
Retinopathy was absent in all cases. Ages ranged from 8 to 76 years
(mean, 47 years); nine males and one female. The time between
diabetes diagnosis and first renal symptoms was 0 to 10 years (mean, 3.5
years). The clinical onset was proteinuria, six cases, nephrotic syn-
drome, three, and acute renal failure, one. Hypertension was present in
three cases and proximal tubular disorder in two. Histological diagnosis
included light, electron, and immunofluorescence microscopy. Diabetic
nephropathy, diffuse intercapillary lesion, was present in three cases;
minimal change disease, one case; membranous nephropathy, three
cases; membranous nephropathy with antitubular basement membrane
antibody, one case; endocapillary GN, one case; diabetic nephropathy,
nodular lesion, with mesangial IgA deposits, one case. In summary,
glomerular involvement in diabetes may represent : 1) a second renal
lesion superimposed to diabetic nephropathy, 2) strong association of
membranous nephropathy to diabetes, 3) other primary ON unrelated
with diabetes and 4) the absence of retinopathy does not exclude, in
some cases, diabetic nephropathy.
Lens abnormalities (LA) in renal transplantation. J. L. Teruel, J. A.
Perez Rodriguez, R. Martin, F. Liaflo, R. Marcén, C. Quereda, andf.
Ortuno. Servicio de Nefrologia, Centro Ramón y Cajal, Madrid, Spain.
We have studied the incidence of LA in 82 transplant patients with
normal renal function. The follow-up period ranged between 3 and 54
months. LA were observed in 32 patients: the most frequent findings
were posterior subcapsular cataract (15 cases) and vacuolar lens
degeneration (9 cases). The prevalence of LA increases from 8% in the
basal study up to 43% at the end of first year, remaining stable
thereafter. The onset of LA was well determined in 19 cases, 95% of
them during the first year. Cumulative dose of oral prednisone was
similar in patients with and without LA (169 36 vs. 158 39mg/kg),
but the dose of intravenous metilprednisolone (MP) was higher in the
former (102 74 vs. 39 40 mg/kg, P < 0.01). The incidence of LA
was also higher in patients who have had transient steroid diabetes
episodes (67 vs. 34%, P < 0.01). In conclusion: 1) LA usually appears
during the first year after renal transplantation, 2) There is a 43%
prevalence at the end of first year, remaining stable thereafter, and 3)
Total dose of i.v. MP and steroid diabetes are the main risk factors to
develop LA.
Value of HTA as isolated factor of cardiovascular risk in HD. L. Orte,
F. Garcia, R. Matesanz, andf. Ortuño. Servicio de NefrologIa, Centro
Ramón y Cajal, Madrid, Spain. A comparative study was carried out
between 17 cardiovascularly dead patients on HD (group A: 10 male, 7
female; mean age, 45 13 yr.; mean time on HD, 24 15 months), and
a control group (B) similar in sex, age, time on HD, and nephropathy.
At entry, the percentage of previous hypertensives and smokers was
analogous. There were no differences in biochemical cardiovascular
risk factors. We evaluated overall HD evolution: systolic (BPs), dias-
tolic (BPd), and mean blood pressure (BPm) at the beginning and end of
all sessions; interdialysis overweight, and need of antihypertensive
medication. BPm was lower in group B (P < 0.01), and with a lesser
significance (P < 0.05) BPs initial and final, BPd initial, and BPm final.
In group A, 12 patients (70%) needed antihypertensive drugs and only
seven (41%) from group B, remaining hypertensives 11(92%) and two
(29%), respectively. No differences were found in overweight between
groups. Arterial hypertension in HD, and specifically initial mean BP, is
the most important factor in cardiovascular risk of these patients and its
control needs priority.
Short hypertonic hemodialysis (HD). M. Garcia, M. Carrera, j. M
Pons, R. Deulofea, E. Merola, X. Company, J. Bonal, P. Arrizabalaga,
and L. Revert. Hospital Clinico y Provincial, Universidad de
Barcelona, Barcelona, Spain. We studied the effects of changing from
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conventional HD of 4 hr x 3/week to hypertonic HD of 3 hr x 3/week
on clinical tolerance and small and middle molecules. Characteristics of
hemodialyzer and dialysate buffer were not modified during this study.
Six patients weighing 55.8 5.4 kg and having a renal residual function
of 0.19 0.26mI/mm were examined. Hypertonic HD was carried out
by perfusing 342 mEq of NaCI into blood during the first hour of HD to
increase plasma osmolality and using a dialysate containing 130
mEq/liter of Na. Plasma BUN, creatinine, K, Na, P, and uric acid were
tested fortnightly. To assess middle molecules, the peak b4-2 was
evaluated every 2 months using a two-stage chromatographic proce-
dure: first Gel-sieve (Sephadex G15) and second ion-exchange (DEAE
Sephadex A-25). The patient's control period on conventional HD
lasted 4.5 months and the same patients had been on hypertonic HD for
8.5 1,5 months. The following results were obtained when conven-
tional HD (N = 351) was compared to hypertonic HD (N = 588):
Interdialytic weight gain: 2217 354 vs. 2412 155 g; incidence of
hypotension: 19.1 vs. 5.7% (P < 0.001); headache: 19.9 vs. 14.8% (P <
0.01); post-dialysis astenia: 36.4 vs. 15.4% (P < 0.001); and increased
usual thirst: 7.1 vs. 8.1%. Small solutes, except P that passed in 6
months from 5.5 1.7 to 6.8 1.3 mg/dl, did not increase. The peak
b4-2 changed in 4 months from 2182 780 to 2087 1178 mm2/ml. We
conclude that short hypertonic HD offers a good clinical tolerance
keeping the levels of small and middle molecules, except in the case of
P that requires a highest dose of (OH)3A1. It is an effective way to
improve the quality and to reduce the length of HD.
Distribution of body compartments on different types of hemodialysis
(HD). M. Garcia, M. Carrera, C. Piera, R. Deulofeu, X. Company, J.
M Pons, J. Setoain, and L. Revert. Hospital ClInico y Provincial,
Barcelona, Spain. The changes in plasma volume (PV), extracellular
volume (ECV), and intracellular volume (ICV) were evaluated on
conventional HD and hypertonic HD. Thirteen patients were studied.
Six, weighing 58.8 5.2 kg had been for 1 month on hypertonic HD 3
hr x 3/week using a dialysate with 130 mEq/liter of Na and 295
mOsm/liter and perfusing 342 mEq of Na into blood during the first hour
of HD. Seven, weighing 65.5 9.4 kg were on conventional HD 4 hr x
3/week with a dialysate containing 138 mEq/liter of Na having an
osmolarity of 305 mOsm/liters. One hr before HD, the spaces of
RIHSA-25I (PV), 35SONa2 (initial ECV), and H20 (total water) were
determined. The plasma albumin was measured hourly and at the end of
HD the space of 35SO4Na2 (final ECV) was again tested. ICV = Total
water—initial ECV. In conventional HD with weight loss of 1900
387, PV and ECV diminished 14.5 6.4 and 19.2 6.3, respectively,
and ICY increased 1.7 3.3%, showing that weight loss was exclu-
sively due to ECV with a subsequent hyperhydration of ICY. In
hypertonic HD with weight loss of 1866 668 g PV, ECV and ICV
decreased 5.4 4.5, 10.4 7.4 and 3.4 3.8%, respectively,
indicating that weight loss was due to ECV in 54% and to ICY in 46%.
Hypertonic HD in contraposition to conventional HD allows dehydra-
tion of the intracellular compartment and maintains better than PY
during HD. Isotopic techniques were useful for evaluating the distribu-
tion of weight loss.
Adrenergic control of serum potassium in chronic renal failure: Effect
of salbutamol. J. Montoliu, L. Andreu, J. López-Pedret, and L. Revert,
Hospital Clinic, Barcelona, Spain. Beta adrenergic receptors modulate
intracellular potassium (K) uptake in chronic renal failure (CRF) (Proc
EDTA 19:756, 1982; 20:572, 1983). To further investigate the effect of
specific beta-2 stimulation on K metabolism, we gave salbutamol (5),
0.5 mg i.v. in 10 mm, to a group of 12 essentially anuric non-diabetic
patients with CRF on maintenance hemodialysis (HD) 72 hr after their
last HD. Thirty mm after the S injection, the patient's serum K dropped
from a mean pre-injection value of 5.5 0.7 mmole/liter (± SD) to a
mean final value of 4.4 0.7 mmole/liter (mean decrement in serum K
1.1 mmole/liter, P < 0.001). Individual changes in serum K ranged from
—0.7 to — 1.8 mmole/liter. Serum insulin and glucose also increased
(23.1 9.6to67.7 4l.9sU/mland90.1 l0.9to 128.1 25.4mg/dI
respectively, P < 0.01 for both), but the increment in serum insulin and
the decrement in serum K were not correlated. The S injection was
generally well tolerated. Thus, S has a rapid and significant K lowering
effect in CRF, which is probably mediated by direct beta-2 adrenergic
facilitation of intracellular K uptake. However, an increase in insulin
secretion could intervene also. Salbutamol might be useful in the acute
treatment of hyperkalemia in CRF.
Differential diagnosis of amyloidosis: The value of potassium
permanganate (PP) test in amyloid tissue. M. T. Gonzalez, R. Poveda,
M. Carrera, J. Torras, D. Serón, S. Sancho, D. Podzamzcer, J. Mauri,
and J. Alsina. Nephrology and Pathology Departments, Hospital de
Bellvitge, Barcelona, Spain. The affinity to Congo red of amyloid tissue
obtained from 30 patients was studied after incubation in PP. The
results of the test were correlated with the clinical type of amyloidosis.
The patients were classified as follows: three had primary amyloidosis,
six amyloidosis associated to myeloma, and 21 secondary amyloidosis.
From this last group, seven had rheumatoid arthritis, six
bronchiectasis, two tuberculosis, two chronic osteomyelitis, two
ankylosisng spondylitis, one ulcerative colitis, one chronic pyelonephri-
tis with pyonephrosis, one hypernefroma, and one Weber-Christian
disease. The affinity to Congo red was unchanged in the three cases of
primary amyloidosis and in five of the six cases associated to myeloma,
and disappeared in all cases of secondary amyloidosis. We conclude
that the PP test is useful to differentiate primary amyloidosis and
amyloidosis associated to myeloma from secondary amyloidosis. The
results confirm the sensibility of AA deposits and the resistance of AL
deposits to PP.
Follow-up of diabetic nephropathy (DN) in an endocrinologic and
nephrologic unit. M. T. Gonzalez, A. M. Castelao, J. Torras, D. Serón,
G. Vinzia, J. Soler, and J. Alsina. Nephrology and Endocrinology
Department, Hospital de Bellvitge, Barcelona, Spain. We studied 74
patients with DN between January, 1980, and December, 1983, in an
endocrinologic and nephrologic unit. When first admitted, these pa-
tients had an important degree of renal failure (plasma creatinine level:
285 207 mole/liter). We compared patients with type I diabetes (D)
to those with type II, and studied the factors that could have a
prognostic relevance in the evolution of the DN as: proliferative
retinopathy (P < 0.001), nephrotic syndrome (P < 0.025), hypertension(NS), the interval between the beginning of D and the diagnosis of DN
(P < 0.001). The higher incidence of the factors in type I D correlated
well with the more frequent occurrence of end-stage renal failure in this
group. We also studied the results of substitutive therapy (CAPD, IPD,
HD, RT). Dialysis was associated with a high mortality in type I D.
Better results are achieved with renal transplantation in these patients.
The study of diabetic patients with DN by a team of nephrologists and
endocrinologists provides them an accurate control and a more suitable
therapy.
Plasma exchanges (PE) in the treatment of rapidly progressive glomer-
ulonephritis (RPGN). J. M. Mauri, M. T. Gonzalez, R. Poveda, J.
Torras, D. Serón, E. Andrés, J. Andájar, and J. Alsina. Nephrology
Department, Hospital de Bellvitge, Barcelona, Spain. Twenty patients
with RPGN and severe renal impairment are reported. Twelve cases
were considered idiopathic, seven had a positive immunofluorescence
(IF), five had a negative IF, and in eight cases a vasculitis could be
demonstrated. All patients received prednisone (1 mg/k body wt) and
cyclophosphamide (2 mg/k body wt.). An intensive PE regime was
applied in 11 cases: two positive IF-RPGN, four negative IF-RPGN,
and five cases of vasculitis. Improvement was seen in five out of six
PE-treated idiopathic RPGN, four of them showing a negative IF
pattern. In three, a sustained improvement was appreciated, and two
went into ESRF after 17 and 33 months. In the group of six idiopathic
RPGN on which PE were not carried out, three patients died and three
did not show any improvement. Renal function improved in two
patients with RPGN-vasculitis associated treated by PE. In one case,
improvement remains 34 months after treatment, but in the other case,
a progressive loss of renal function was observed, starting HD 5 months
after. In the three other cases, no changes were seen in one and two
patients died. From these results some beneficial effects of PE treat-
ment in idiopathic RPGN, mainly in its negative IF form, would be
suggested. The effectiveness of PE in the treatment of RPGN-vasculitis
associated could not be determined.
Arachidonic acid (AA) metabolism and platelet function in uremia:
Effect of different types of dialysis and kidney transplantation. X. Sarrias,
F. Martinez-Brotons, C. Reynaldo, J. Gabás, J. M. Griñó A. M.
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Castelao, E. Andrés, L. Carreras, A. M. Amenós, H. Rama, J. Alsina.
Servicio de Nefrologia y Hematologla, Hospital de Bellvitge Hospitalet
Nefrologla Alianca Mataronina, Mataró, Spain. An abnormal AA
metabolism in platelet uremic patients has been reported. We have
verified this abnormality and studied the effects of several types of
treatment. Thromboxane B2 (TxB2) and/or malondialdeyde (MDA)
production and AA and collagen-induced secretion of serotonine were
measured and also the percentage aggregation in response to these
agents. Fifteen healthy subjects, 15 patients before and after
hemodialysis (HD), four on continuous peritoneal dialysis (CAPD),
three on intermittent peritoneal dialysis (IPD), and 13 successful
transplants were studied. After HD we found the correction of TxB2
and MDA synthesis, but only a light, not significant, increase on
serotonine secretion and platelet aggregation. The role of heparin in
these effects was found to consist only on a non-significant increase of
aggregation. Patients on CAPD showed normal results, except for
significant reduction of aggregation in response to AA. IPD had better
pre-dialysis results than HD, but they got worse just after it. We have
no explanation for it. After renal transplantation patients did not differ
in any way from controls.
Enzyme urine activity in acute renal failure (ARF). A. M. Castelao, F.
Barragan, J. Fuentes, J. Orts, J. M. Baucells, and J. Alsina. Depart-
ments of Nephrology and Biochemistry, Hospital Bellvitge, Hospitalet
LL, Barcelona, Spain. The study of urinary enzymes has been pro-
posed as a diagnostic aid in renal diseases, especially in tubular damage.
We have studied the urinary enzyme excretion in 53 patients with ARF.
Thirty five were male and 18 female, aged 58 13 yr. The patients were
distributed in two groups: 34 patients with established ARF (EARF)
NAG Lysozyme
EARF 475 564 skat/mole cr 1156 1733 kat/mole cr
PRF 205 401 skat/mole cr
0.02 < P < 0.05
213 460 skat/mo1e cr
P < 0.001
and 19 with pre-renal failure (PRF). Specimens were collected in the
first morning urine in all patients. The enzymes studied were:
alanineaminopeptidase (AAP), alkaline phosphatase (ALP), gam-
maglutamyltranspherase (GOT), nacetyif3dglucuronidase (NAG),
lysozyme (LYS), lactate dehydrogenase (LDH). We have found in-
creased excretion of NAG and LYS in both groups, being superior in
EARF (statistical comparison being significant). There were not signif-
icant differences in the excretion of the remaining enzymes in both
groups. We think that NAG and LYS are good markers of tubular
damage, sequential monitoring being useful as an index of tubular
function recovery.
The effect of antidiuretic hormone (ADLI) on Na and K movements
across human red cell (HRC) membranes. J. Diez, C. Miqueo, M. Goni,
R. Virto, A. Monzón, P. Errasti, and A. Purroy. University Clinic,
Pamplona, Spain. It has been suggested that ADH may modulate NaCI
transport across the renal tubule cells. We examined effects of ADH on
Na and K transport systems of HRC. At l0 to 10'°M, ADH
decreases total Na efilux (20 3%). Such an effect is due to decrease
of ouabain-sensitive Na efflux (15 5%) and to decrease of
bumetanide-sensitive Na efiuux (control cells: 285 15 mole/liter cells
xh'; cells incubated with ADH: 181 18; P <0.05). In addition, we
have found that external cyclic AMP 2 mM decreases bumetanide
sensitive NA effiux (30 12%). These results suggest that in HRC in
which endogenous levels of cyclic AMP are modulated by hormones,
the furosemide and bumetanide-sensitive Na, K, Cl cotransport system
may be influenced by ADH. Further studies are required to determine
the significance of the above findings when considering the effect of
ADH on renal tubule cells.
Renal osteodystrophy in continuous ambulatory peritoneal dialysis
(CAPD). Comparative study with hemodialysis patients. C. Gonzalez, E.
Gimenez, F. Rivera, S. Garcia, F. Picazo, J. Olivares. Hospital de
Alicante, Alicante, Spain. In 25 patients treated with CAPD during
more than 6 months (18 8), we studied the evolution of renal
osteodystrophy in comparison with 18 patients in hemodialysis. Both
groups had similar age, sex, etiology of renal disease, and time on
dialysis. We determined Ca, P. alkalina phosphatase (AP), iPTH, and
skeletal radiology at similar intervals. Peritoneal loss of P (325 63
mg/24/hr) was related to serum P (P 0,001), obtaining lower serum P
levels in CAPD group. We do not find differences in the levels of iPTH,
AP, and Ca (8.7 0.9 vs. 8.9 0.4 mg%). But the CAPD patients
develop hypocalcemia and elevation of AP during the first months. The
peritoneal Ca balance (—12 to +200 mg/24/hr) is related to serum Ca (P
0.001). AP lowers at long term in CAPD group. The frequency of initial
radiologic osteitis fibrosa is similar. With HD it increases and with
CAPD it diminishes and no new case appears. In summary, CAPD
controls well both hyperphosphoremia and hyperparathyroidism if
hypocalcemia is treated with oral calcium and/or Vit D.
Acute renal failure (ARF) after radiologic contrasts (RC) use. J.
Torras, A. M. Castelao, R. Romero, E. Andrés, J. Alsina. Department
of Nephrology, Hospital De Bellvitge, Barcelona, Spain. Acute renal
failure due to RC is a known feature in radiology, but the rate and
etiologies are not well established. 35 patients who developed ARF
after a diversity of trials with RC were studied retrospectively, in a
four-year interval. The risk factors evaluated were age, pre-existing
renal impairment (RI), diabetes mellitus (DM), hypertension (Hy),
arteriosclerotic arteriopathy, high blood uric acid, proteinuria diuretic
or aminoglicoside administration, and hepatopathy. RI was present in
62.8% of the patients, Hy was in 57% and 25.7% had arteriopathy.
Seven patients (20%) had DM, ARF was oliguric in 16 patients, and it
developed during the first 24 hr. Six patients underwent dialysis, in a
total of 24 hr. Six patients underwent dialysis, in a total of 24 sessions.
Two patients died because of their main illness. 80% of the patients
ameliorate renal function at previous rates. Results suggest: 1) RI is the
most prevalent risk factor in ARF after RC use; 2) renal arteriopathy
and renal hypoperfusion of several etiologies (DM, arteriosclerosis)
seem to predispose to ARF after RC use; and 3) renal function recovers
to previous rates in a few days.
Continuous arteriovenous hemofiltration (CAVIIF) in patients with
acute renal failure. J. M. López-GOmez, S. G. Vinuesa, V. Barrio, M.
Sanchez, E. Junco, J. Luno, M. A. Alvarez, A. Franco, and F.
Valderrabano, Hospital Provincial, Madrid, Spain. Twelve patients
with oliguric acute renal failure were treated with CAVHF using an
amicon hemofilter of 0.25 cm2. The most frequent vascular access was
femoral and Buselmeier external shunt. Continuous heparine infusion in
the arterial line at a rate of 500 to 1000 U/hr was used. Protamine
continuous infusion pump was used in the venous line in two high
bleeding risk patients. Treatment ranged from 31 hr to 20 days (i = 97
hr) with a mean duration of hemofilter device of 51.8 hr. Mean
ultrafiltration rate was 8.499 mi/day. No significant differences were
found between venous, arterial, and ultrafiltrate samples for urea,
creatinmne, and electrolytes except for an elevated calcium concentra-
tion in the venous line and for chloride and total CO2 in the ultrafiltrate.
Fluid reposition consisted of pentoneal dialysis solution, hypertonic
glucose, and aminoacids. No patients needed hemodialysis during the
treatment with CAVHF. No changes in blood pressure or p02 were
produced and only one patient presented a gastrointestinal bleeding,
which required discontinuation of the procedure. We conclude that
CAVHF is effective in the management of acute renal failure patients.
It allows a continuous fluid removal, perserves hemodynamic stability,
and it can compensate the oligunc renal failure.
Renal disease in heroin addicts. J. M. LOpez-GOmez, S. G. Vinuesa,
V. Barrio, E. Niembro, T. Grau, J. Solares, F. Valderrdbano. Hospital
Provincial, Madrid, Spain. Twenty-two out of 138 heroin addict pa-
tients presented evidence of renal disease. Percutaneous or postmortem
kidney biopsies were performed in 12 cases. Among 13 patients who
presented with proteinuria or nephrotic syndrome along with micro-
scopic hematuria, five showed diffuse and two focal proliferative
glomerulonephritis (GN) and focal segmental glomeruloscierosis (FSG)
was present in two. The proliferative GN were associated to
staphylococcus aureus endocarditis with hypocomplementemia and the
course was complicated by acute renal failure because of sepsis or
nephrotoxic drugs. The cases with FSG had normal complement levels
and none was septic. Compatible changes with septic shock were found
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in the postmortem studies of three patients. 45% of the patients with
renal involvement disclosed serum virus B markers, but only one had
positive anti-HBsAg deposits by immunoflorescent studies. High levels
in serum 1gM were found frequently and it was unrelated to histological
findings. Ten out of 15 patients who developed acute renal failure died.
The cases with only glomerular involvement had no impairment in renal
function and in one patient with FSG, the nephrotic syndrome disap-
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peared after cessation of heroin addiction. We conclude that heroin
addiction is increasing and carries an important risk of renal disease.
Different histological findings are present in relation to heroin toxicity,
its vehicles, or, more frequently, to sepsis. The heroin-associated
nephropathy could improve after discontinuation of drug addiction. The
association with acute renal failure is frequent and has a high mortality
rate.
